The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment

Abstract The importance of B cells in multiple sclerosis (MS) has been demonstrated through the advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human anti-CD20 monoclonal antibody (mAb) developed and tested for subcutaneous (SC) self-administration at monthly d...

Full description

Bibliographic Details
Main Authors: Stephen L. Hauser, Ludwig Kappos, Amit Bar-Or, Heinz Wiendl, David Paling, Mitzi Williams, Ralf Gold, Andrew Chan, Ron Milo, Ayan Das Gupta, Goeril Karlsson, Roseanne Sullivan, Gordon Graham, Martin Merschhemke, Dieter A. Häring, Patrick Vermersch
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-07-01
Series:Neurology and Therapy
Subjects:
ALITHIOS
Anti-CD20 monoclonal antibody
ASCLEPIOS I/II
Benefit-risk
Ofatumumab
Relapsing multiple sclerosis
Online Access:https://doi.org/10.1007/s40120-023-00518-0

Internet

https://doi.org/10.1007/s40120-023-00518-0

Similar Items